Article Text

Download PDFPDF

Association of vascular access flow with short-term and long-term mortality in chronic haemodialysis patients: a retrospective cohort study
  1. Chung-Kuan Wu1,2,3,
  2. Chia-Lin Wu3,4,5,
  3. Chia-Hsun Lin2,6,
  4. Jyh-Gang Leu1,2,
  5. Chew-Teng Kor7,
  6. Der-Cherng Tarng3,8,9
  1. 1Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
  2. 2School of Medicine, Fu-Jen Catholic University, New Taipei, Taiwan
  3. 3Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
  4. 4Division of Nephrology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
  5. 5School of Medicine, Chung-Shan Medical University, Taichung, Taiwan
  6. 6Division of Cardiovascular Surgery, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
  7. 7Internal Medicine Research Center, Changhua Christian Hospital, Changhua, Taiwan
  8. 8Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  9. 9Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan
  1. Correspondence to Dr Der-Cherng Tarng; dctarng{at}vghtpe.gov.tw

Abstract

Objectives To investigate the impact of vascular access flow (Qa) on vascular and all-cause mortality in chronic haemodialysis (HD) patients.

Design Observational cohort study.

Setting Single centre.

Participants Adult chronic HD patients at the HD unit of Shin Kong Wu Ho-Su Memorial Hospital between 1 January 2003 and 31 December 2003 were recruited. Patients were excluded if they had arteriovenous fistula or arteriovenous graft failure within 3 months before the date of Qa measurement, were aged <18 years and had Qa levels of ≥2000mL/min. A total of 378 adult chronic HD patients were eventually enrolled for the study.

Interventions The selected patients were evaluated with Qa and cardiac index (CI). They were divided into four groups according to three Qa cut-off points (500, 1000 and 1500 mL/min).

Primary and secondary outcome measures Short-term and long-term vascular (cardiovascular or cerebrovascular) and all-cause mortality.

Results Qa was positively correlated with CI (r=0.48, p<0.001). A Qa level of <1000 mL/min was independently associated with 1-year all-cause mortality (adjusted OR, 6.04; 95% CI 1.64 to 22.16; p=0.007). Kaplan-Meier analysis revealed that the cumulative incidence rates of all-cause and vascular mortality were significantly higher in the patients with a Qa level of <1000 mL/min (log-rank test; all p<0.01). Furthermore, a Qa level of <1000 mL/min was independently associated with long-term all-cause mortality (adjusted HR, 1.62; 95% CI 1.11 to 2.37; p=0.013); however, the risk of vascular mortality did not significantly increase after adjustment for confounders.

Conclusions Qa is moderately correlated with cardiac function, and a Qa level of <1000 mL/min is an independent risk factor for both short-term and long-term all-cause mortality in chronic HD patients.

  • access flow
  • all-cause mortality
  • cardiovascular mortality
  • cardiac index

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors reviewed the manuscript. C-KW collected and interpreted the data and wrote the manuscript. C-LW and C-TK ran the data, performed statistical analyses and helped to write the manuscript. C-KW and C-LW determined the concept and design of this study. C-KW, C-LW, C-HL, J-GL and D-CT contributed to the discussion and manuscript revision. D-CT and C-LW conceived the study and are the guarantors of this publication.

  • Funding This study was supported by grant SKH-8302-102-DR-05 from the Shin-Kong Wu Ho-Su Memorial Hospital Research Foundation, the Novel Bioengineering and Technological Approaches to Solve Two Major Health Problems in Taiwan sponsored by the Taiwan Ministry of Science and Technology Academic Excellence Program (MOST 105-2633-B-009-003), and Foundation for Poison Control.

  • Competing interests None declared.

  • Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

  • Ethics approval The study was approved by the institutional review board of Shin Kong Wu Ho-Su Memorial Hospital (approval number 20160104R).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.